TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04659941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Using aseptic methods, 1 mL of Sterile Water for Injection, is added to one vial of vaccine. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Drop the immunizing dose of 0.1 mL of BCG VACCINE from the syringe and needle onto the cleansed surface of the skin.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (NaCl) saline solution
Description: A 0.1 ml of 0.9% NaCl saline solution applied intradermally in the lower insertion of the deltoid muscle of the right arm will be used as placebo, except contraindications or impossibilities.
Study: NCT03103451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-121
Study: NCT03576391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Arm Movements
Description: 2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Arm Movements
Description: 2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical fatigue condition
Description: 40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive fatigue condition
Description: 45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
Study: NCT03925220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The SUPPER Project
Description: Substance Use Promoted by Eating family meals Regularly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improving nutrition and physical activity among youth
Description: A brief intervention focused on improving nutrition and physical activity among youth
Study: NCT03679377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular slotplate
Description: Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
Study: NCT02974114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and caffeine
Description: Test product containing 500 mg paracetamol and 65 mg caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Test product containing 500 mg paracetamol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match paracetamol 665mg sustained release tablets
Study: NCT02602184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR/101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00818623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
Study: NCT02832856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationship Education
Description: RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationship Education
Description: RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job Readiness Curriculum
Description: Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Job Readiness Curriculum
Description: Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills.
Study: NCT02534779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Insert
Description: Placebo insert
Study: NCT02934750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pursed lip breathing
Description: Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~1. Breathe in through your nose (as if you are smelling something) for about 2 seconds.~2. Pucker your lips like you're getting ready to blow out candles on a birthday cake.~3. Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~4. Repeat.
Study: NCT01909622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No vitamin D
Study: NCT03318692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spondylodesis
Description: Dorsal instrumentation with transpedicular screws (spondylodesis)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spondylodesis
Description: Dorsal instrumentation with transpedicular screws (spondylodesis)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT
Description: CT of operated area is performed within 7 days of surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: CT of operated area is performed within 7 days of surgery
Study: NCT04566835

Intervention type: OTHER
Group type: OTHER
Intervention: Standart Care given during normal examination
Description: This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standart Care given during normal examination
Description: This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Program with cartoon education for Children with Asthma
Description: First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
Study: NCT01032369

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional intervention and physical activity
Description: Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention, physical activity and behavioral treatment
Description: Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions.
Study: NCT01650324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108
Description: DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
Study: NCT01333241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle behavior interventon grop

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Comparator: Control group
Study: NCT01586741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quill suture application for repair or polypropylene mesh
Description: The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quill suture application for repair or polypropylene mesh
Description: The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
Study: NCT03890185

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemo + Low dose RT
Description: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemo + Low dose RT
Description: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo alone
Description: Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
Study: NCT00871871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to HCTZ
Description: Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to HCTZ
Description: Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
Study: NCT00871871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Description: ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
Study: NCT03103451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02533531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Lead Patch
Description: The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
Study: NCT04771728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole vaginal suppositories
Description: Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)
Description: Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
Study: NCT00376831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, Fentanyl
Description: fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KETAMINE, MIDAZOLAM
Description: Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
Study: NCT00669682

Intervention type: OTHER
Intervention: Congestive heart failure
Description: Spontaneous occurrence of fluid overload.
Study: NCT00578461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara C
Description: 3000 mg/m\^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI-Total Body Irradiation
Description: Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
Study: NCT03337451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-305
Description: Patients will receive study drug every 4 weeks
Study: NCT01405365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 400mg TID for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill TID for 10 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
Study: NCT01405365

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planning
Description: Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
Study: NCT00871871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to ISMN
Description: Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to ISMN
Description: Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
Study: NCT02914977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: * Agent: Daunorubicin~* Dose: 6.75 mg/m2/day~* Route: IV~* Schedule: Days 1-5~* Duration: One cycle
Study: NCT00825825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
Study: NCT00259714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dialysate sodium individualization
Description: Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized).
Study: NCT00825825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
Study: NCT00259714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dialysate sodium
Description: The prescribed dialysate sodium is 140 mEq/L
Study: NCT03170726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arveles
Description: Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arveles
Description: Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arveles
Description: Intraoperative and postoperative pain values between these three groups will be compared.
Study: NCT00825825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two weeks of placebo taken orally.
Study: NCT00882687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Ophthalmic Solution
Study: NCT03170726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrafen 800 mg
Description: ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrafen 800 mg
Description: ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrafen 800 mg
Description: ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasebos
Description: normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasebos
Description: normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: plasebos
Description: normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
Study: NCT00882687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Ophthalmic Solution
Study: NCT00790426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT02633670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Hemopatch
Study: NCT00882687

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic Solution
Study: NCT03402815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
Study: NCT02622009

Intervention type: PROCEDURE
Intervention: BRONCHOSCOPIC PROCEDURE
Description: After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina

Intervention type: PROCEDURE
Intervention: BRONCHOSCOPIC PROCEDURE
Description: After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina